Thyroid hormone and arrhythmogenic activity  by Auer, Johann et al.
there is evidence for S-RV in stable angina (3,5), and relative
insufficiency probably is an invalid mechanism; cholesterol- and
stress-reduction significantly improved angina in a month’s time
(6), long before CAD could be improved—a finding incompatible
with classic relative insufficiency (3,5). Favorable to the concept,
cholesterol reduction favors vasodilation and can improve vasodi-
lation in one month (7) and, as stress can cause S-RV (3),
stress-reduction reasonably is vasodilative. Also, while plaque
rupture/thromboses are the accepted mechanisms of acute coro-
nary syndromes, a recent analysis showed significant faults with
this mechanism (5). For example, studies of infarction showing
rising incidences of thromboses over time are incompatible with
primary thromboses. If thromboses cause infarction, how can their
incidence increase over time? And recognition of S-RV during
ischemic episodes in unstable angina (8) is consistent with the
S-RV cause of this angina.
The S-RV concept offers an explanation for the only occasional
occurrence of vasospastic angina, and a viable explanation should
help establish the reasonableness of the concept. As vasospastic
angina is unassociated with CAD, this major vasoconstrictive
force is absent, and angina occurs only when there are high
levels of other risk factors as stress, gender and genetic factors,
etc.—which occur only occasionally. In IHD associated with
CAD, symptoms are attributed to the risk factor of CAD plus
other risk factors such as stress; consistent with this, induced
stress can cause myocardial ischemia in individuals with stable
angina (9,10). Also, absence of IHD in many individuals with
severe CAD is explained by the relative absence of other risk
factors such as stress.
Although considerable evidence supports the standard position,
there appears to be sufficient contravening evidence for the S-RV
concept to prompt a comprehensive review of its positions.
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Thyroid Hormone and
Arrhythmogenic Activity
We read with great interest the study by Chen et al. (1) in a recent
issue of the Journal. The investigators report that thyroid hormone
changes the electrophysiologic activity of the pulmonary vein
cardiomyocytes, and they suggest that increased tri-iodothyronine-
induced automaticity and enhanced triggered activity may increase
the arrhythmogenic activity of cardiomyocytes in hyperthyroidism.
They conclude that this mechanism contributes to arrhythmogenic
activity of hyperthyroidism.
Hyperthyroidism is known to be an important risk factor in the
etiology of atrial fibrillation (AF)(2). In a large retrospective study
investigating an unselected, community-based population of older
persons (3), we could demonstrate that the prevalence of AF was
2.3% in subjects with normal values for serum thyrotropin, 13.8%
in patients with overt hyperthyroidism (both low serum thyro-
tropin values [0.03 mU/l] and elevated free tri-iodothyronine
and free thyroxine concentrations), and 12.7% in patients with
subclinical hyperthyroidism (low values of serum thyrotropin
[0.4 mU/l], and free tri-iodothyronine and free thyroxine con-
centrations within the normal range). The relative risk of AF in
subjects with subclinical hyperthyroidism, compared with those
with normal concentrations of serum thyrotropin, was 5.2 (95%
confidence interval [CI] 2.1–8.7, p  0.01). Thus, a low serum
thyrotropin concentration was associated with a more than five-
fold higher likelihood for the presence of AF, with no significant
difference between subclinical and overt hyperthyroidism.
Individuals with low serum concentrations of thyrotropin re-
gardless of concentrations of free tri-iodothyronine and free
thyroxine should be considered as a population at risk for the
development of AF (4). Thus, thyroid secretion needs not increase
much, if at all, and serum concentrations of free tri-iodothyronine
and free thyroxine can stay within normal values for AF to occur.
Moreover, when AF occurs, there is only rarely either concurrent
or subsequent overt hyperthyroidism, but it is more commonly
associated with subclinical hyperthyroidism (5). We consider this
topic important, because subclinical hyperthyroidism is, at all,
more common than overt hyperthyroidism among people over age
60 (5) and does not progress to overt hyperthyroidism in most
cases (6).
We agree with Chen et al. (1) that L-tri-iodothyronine-induced
increased automaticity and enhanced triggered activity may be one
mechanism that could increase the arrhythmogenic activity of
cardiomyocytes in overt hyperthyroidism. But it is obvious from
clinical data that mechanisms, other than those triggered by free
tri-iodothyronine and free thyroxine, are important in AF associ-
ated with low serum thyrotropin.
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REPLY
Auer et al. (1) investigated the relationship between subclinical
hyperthyroidism and atrial fibrillation (AF), and they concluded
that subclinical hyperthyroidism has a risk of AF. They also
speculated that the thyroid hormone may have little effect on the
genesis of AF in subclinical hyperthyroidism. We appreciated the
comment from Auer and colleagues. However, in the study from
Auer et al. (1), 65% of patients with AF were associated with other
heart diseases (coronary artery disease, dilated cardiomyopathy and
valvular heart disease), and about half of these patients had atrial
enlargement. Thus, AF in these patients may be due to the
combined effects of thyroid hormone and underlying heart dis-
eases.
Subclinical hyperthyroidism refers to a state with normal
thyroid hormone concentrations and low serum thyrotropin con-
centration. Several causes of subnormal thyrotropin do not reflect
the presence of subclinical hyperthyroidism. Serum thyrotropin
concentrations are frequently low in patients with severe non-
thyroid illness, especially those receiving glucocorticoid. In
addition, low serum thyrotropin value may be associated with
low or normal serum thyroid hormone in the early stage or
shortly after treatment or spontaneous resolution of overt
hyperthyroidism (2). In the study from Auer et al. (1), all the
patients had underlying thyroid diseases of functional autonomy
or autoimmune. It is difficult to diagnose these patients from
limited blood samplings, and subclinical hyperthyroidism may
be overestimated.
Subclinical hyperthyroidism has been considered to have in-
creasing risk of AF. In the follow-up of 10 years, there was a
threefold relative risk of AF in these patients (3). The negative
feedback relationship between serum thyrotropin and thyroid
hormone is log linear. Thus, the patients with slight excess of
thyroid hormone would have low thyrotropin level, but would have
serum thyroxine and tri-iodothyronine concentrations above the
mean values for normal subjects but within the normal range.
Patients with subclinical hyperthyroidism still have symptoms
owing to the biologic effects of thyroid hormone. This means that
patients with subclinical hyperthyroidism may still have excess
thyroid hormone, and thyroid hormone can induce AF.
Although this experimental hyperthyroidism is not completely
similar to usual hyperthyroidism, we investigated the direct effects
of thyroid hormone on the electrophysiologic characteristics of
pulmonary vein and atrial cardiomyocytes (4). We believe that
thyroid hormone increases the arrhythmogenic activity of pulmo-
nary vein cardiomyocytes, which may underlie the occurrence of
AF in hyperthyroidism.
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Manifestation of Left Main Coronary
Artery Stenosis Is Diffuse ST Depression
in Inferior and Precordial Leads on ECG
In the November 1, 2001, issue of the Journal of the American
College of Cardiology, Yamaji et al. (1) reported on a novel
electrocardiographic (ECG) sign for prediction of acute ischemia
caused by left main coronary artery obstruction. They found that
ST elevation in lead aVR with less ST elevation in lead V1 is a
predictor of left main obstruction. Searching the English-language
literature they found only 42 previous reported patients with acute
left main stenosis. The ECG description in these studies included
right bundle branch block, anterior ST elevation or precordial ST
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